INmune Bio (NASDAQ:INMB) versus Phathom Pharmaceuticals (NASDAQ:PHAT) Critical Analysis

INmune Bio (NASDAQ:INMB) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Profitability

This table compares INmune Bio and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Risk and Volatility

INmune Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Institutional & Insider Ownership

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for INmune Bio and Phathom Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	2	2	1	1	2.17
Phathom Pharmaceuticals	1	0	5	1	2.86

INmune Bio currently has a consensus target price of $8.00, indicating a potential upside of 545.16%. Phathom Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 136.26%. Given INmune Bio’s higher probable upside, research analysts plainly believe INmune Bio is more favorable than Phathom Pharmaceuticals.

Valuation & Earnings

This table compares INmune Bio and Phathom Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50,000.00	659.18	-$45.93 million	($1.67)	-0.74
Phathom Pharmaceuticals	$175.11 million	4.72	-$221.25 million	($2.12)	-4.89

INmune Bio has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Summary

INmune Bio beats Phathom Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About INmune Bio

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.